Abiy Ayele Angelo*, Gashaw Adane, Yeshambel Belyhun, Bisrat Birke Teketelew, Dereje Mengesha Berta, Elias Chane, Negesse Cherie, Mesele Nigus
Cutaneous leishmaniasis (CL) is the most common clinical form of leishmaniasis that causes skin disease. Currently, there is no licensed prophylactic vaccine for CL, as the mechanisms of healing and memory T-cell responses that develop after infection with CL are far from fully understood. A review of the published articles identifying CL vaccine candidates, immuno-dominant antigens and potent vaccine adjuvants is needed to provide comprehensive information. Therefore, we aimed to review vaccine candidates, immuno-dominant antigens and potent vaccine adjuvants for preventing cutaneous leishmaniasis.
First-generation vaccine candidates showed complete protection of the specified animal model. They induced strong T-cell mediated and antibody-mediated humoral immune responses (e.g. Curdlan dectin-1, Total Leishmania Antigen (TLA) and L. infantum heat shock proteins (LiΔHSP70-II)). Almost all second and third-generation vaccine candidates and the immuno-dominant antigens of the parasite and the host enhance T cell-mediated and antibody-mediated immune responses. We also reviewed potent vaccine adjuvants such as Myrrh Silver Nanoparticles (MSNPs) and Imiquimod, which play an important role in enhancing immune responses against Leishmania antigens. The T-cell mediated immune response was significantly induced in various experimental models (e.g. IFN-γ and TNF-α response) and also the humoral arm in some instances (e.g. IgG2). This review thus provides comprehensive information on the efficacy and induction of protective immunity of vaccine candidates, antigenic molecules and vaccine adjuvants against CL. However, there is still a need for a comprehensive understanding of the immuno-pathogenesis of the disease upon vaccination.